NRx Pharmaceuticals, Inc. (NRXP) compared with its closest peers (CNTN, CUE, LFCR, INDP, OKUR). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Tharimmune, Inc. (CNTN) | $174.50M | — |
| Cue Biopharma, Inc. (CUE) | $174.06M | -1.1 |
| Lifecore Biomedical, Inc. (LFCR) | $172.61M | -15.2 |
| Indaptus Therapeutics, Inc. (INDP) | $170.55M | -0.1 |
| OnKure Therapeutics, Inc. (OKUR) | $158.95M | -0.7 |
| Assertio Holdings, Inc. (ASRT) | $151.83M | -1.9 |
| Unicycive Therapeutics, Inc. (UNCY) | $150.32M | -3.4 |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $148.57M | -4.5 |
| Equillium, Inc. (EQ) | $145.20M | -4.0 |
| Spruce Biosciences, Inc. (SPRB) | $141.05M | -1.7 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
NRXP overview · NRXP earnings · NRXP financials · NRXP KPIs · NRXP investor relations · NRXP ownership · NRXP filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.